AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials

Translational Lung Cancer Research

Volumn 5, Issue 1, 2016, Pages 85-88

  Gil Bazo, Ignacio ^a   Rolfo, Christian ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acquired resistance; AZD9291; Epidermal growth factor receptor (EGFR) mutation; Non small cell lung cancer (NSCLC); T790M

Indexed keywords

EID: 84960131224     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2015.07.02     Document Type: Editorial

References (9)

1. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.
2. Finlay MR, Anderton M, Ashton S, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014;57:8249-67.
3. Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 2010;116:1336-43.
4. Wang Z, Chen R, Wang S, et al. Quantification and dynamic monitoring of EGFR T790M in plasma cellfree DNA by digital PCR for prognosis of EGFRTKI treatment in advanced NSCLC. PLoS One 2014;9:e110780.
5. Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitorsensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 2014;120:3896-901.
6. Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive. Available online: https://clinicaltrials.gov/ct2/show/NCT02094261
7. A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3). Available online: https://clinicaltrials.gov/ct2/show/NCT02151981
8. Ramalingam SS, Rukazenkov Y, Thomas K, et al. A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. J Clin Oncol 2015;33:abstr TPS8102.
9. Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2015;372:1700-9.